Barbara Collins
AstraZeneca
11 Papers
29 Citations
Barbara Collins is an academic researcher from AstraZeneca. The author has contributed to research in topics: Osimertinib & Cediranib. The author has an hindex of 8, co-authored 10 publications.
Chat about Author
Papers
Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study
James Chih-Hsin Yang,Sang We Kim,Dong Wan Kim,Jong Seok Lee,Byoung Chul Cho,Jin Seok Ahn,Dae H. Lee,Tae Min Kim,Jonathan W. Goldman,Ronald B. Natale,Andrew P. Brown,Barbara Collins,Juliann Chmielecki,Karthick Vishwanathan,Karthick Vishwanathan,Ariadna Mendoza-Naranjo,Myung-Ju Ahn +16 more
TL;DR: Osimertinib showed meaningful therapeutic efficacy in the CNS and a manageable safety profile at 160 mg once daily in patients with EGFRm NSCLC and LM and the adverse event and PK profiles were consistent with previous reports for osimert inib.
307
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.
James Chih-Hsin Yang,Frances A. Shepherd,Dong Wan Kim,Gyeong Won Lee,Jong Seok Lee,Gee-Chen Chang,Sung Sook Lee,Yu Feng Wei,Yun Gyoo Lee,G. Laus,Barbara Collins,Francesca Pisetzky,Leora Horn +12 more
TL;DR: Limited patient numbers preclude formal safety and efficacy comparisons between the two treatment arms, and the combination of programmed cell death 1/programmed death ligand 1 inhibitors and EGFR‐TKIs as therapy for NSCLC is not well understood, but it requires a careful approach if considered in the future.
187
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Juliann Chmielecki,Tony Mok,Yi-Long Wu,Ji-Youn Han,Myung-Ju Ahn,Suresh S. Ramalingam,Thomas John,Isamu Okamoto,James Chih-Hsin Yang,Frances A. Shepherd,Krishna C. Bulusu,G. Laus,Barbara Collins,J. Carl Barrett,Ryan J. Hartmaier,Vassiliki A. Papadimitrakopoulou +15 more
TL;DR: In this article , acquired resistance mechanisms to second-line osimertinib (n = 78) in patients with EGFR T790M advanced non-small cell lung cancer (NSCLC) from AURA3 were evaluated.
Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson,Michelle Scurr,Kate Gardner,Elizabeth Barquin,Marcelo Marotti,Barbara Collins,Helen Young,Juliane M. Jürgensmeier,Michael F. Leahy +8 more
TL;DR: In patients progressing on imatinib/sunitinib, cediranib 45 mg/day demonstrated evidence of activity by 18FDG-PET, but did not reduce average SUVmax, and evidence of antitumor activity was seen in ASPS.
66
Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma.
K. Gardner,Ian Judson,Michael F. Leahy,Elizabeth Barquin,Marcelo Marotti,Barbara Collins,Helen Young,Michelle Scurr +7 more
TL;DR: Data demonstrate the promising preliminary activity and safety of chronic administration of cediranib in this disease and further investigation is warranted, particularly as there is no effective systemic treatment for patients with advanced ASPS.
58